RxDoctor Payments Data

Mayer Ballas, MD

Cardiovascular Disease · Forest Hills, NYNPI 1215968318

Payments from drug & device makers

$1,847in general payments, 2019–2025

Across 84 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$535
  • Amgen$438
  • Amarin Pharma, Inc.$259
  • Regeneron Healthcare Solutions, Inc.$210
  • Pfizer$87
  • Boehringer Ingelheim$75
  • plus $241 from 6 others

What the payments were for

  • Food & beverage$1,79997%
  • Education$483%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,847 in reported general payments places this provider in the 50th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$257,020
Medicare patients
613
Services billed
1,834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan156$156,031
Repatha SureclickEvolocumab69$59,466
EliquisApixaban52$56,540
XareltoRivaroxaban42$51,852
VerquvoVericiguat55$50,370
Praluent PenAlirocumab25$18,846
JardianceEmpagliflozin17$18,018
VascepaIcosapent Ethyl26$13,713
Icosapent Ethyl29$6,758
Nebivolol Hcl118$4,223
Ranolazine ErRanolazine32$3,390
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid17$3,083
Valsartan74$2,198
Metoprolol Succinate133$1,520
Rosuvastatin Calcium142$1,519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$43$156,031156 claims
PfizerEliquis$87$56,54052 claims
MerckVerquvo$535$50,37055 claims
Boehringer IngelheimJardiance$75$18,01817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Forest Hills

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →